Bibliographie (2530)
Risk of acute myocardial infarction and ischemic stroke following COVID-19 in Sweden – “the true risk is increased by between three and eight times for acute myocardial infarction and by between three and seven times for ischaemic stroke following COVID-1
vendredi, 30 juillet 2021 15:32 Écrit par Zouhair SouissiRisk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study – The Lancet Invited commentary: What is the association of COVID-19 with heart attacks and strokes? – The Lancet Commentary on Twitter Is Covid a risk factor for heart attack and stroke?https://t.co/6KRaKzPgI5 @TheLancet This […]
The post Risk of acute myocardial infarction and ischemic stroke following COVID-19 in Sweden – “the true risk is increased by between three and eight times for acute myocardial infarction and by between three and seven times for ischaemic stroke following COVID-19.” appeared first on Links Medicus.
Study: Patients who have recovered from COVID-19 may have persistent cognitive symptoms.
vendredi, 30 juillet 2021 15:32 Écrit par Zouhair SouissiCognitive deficits in people who have recovered from COVID-19 – EClinicalMedicine Commentary on Twitter (thread – click for more) We assessed thousands and saw clear evidence of cognitive deficits in people who have recovered from COVID-19. Took a while to appease peer reviewers, but the results stand. Brilliantly led by @HampshireHub. @Amy2Jolly @JoeBarnby @srchamb […]
The post Study: Patients who have recovered from COVID-19 may have persistent cognitive symptoms. appeared first on Links Medicus.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
vendredi, 30 juillet 2021 15:32 Écrit par Zouhair SouissiVaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 […]
The post Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. appeared first on Links Medicus.
Viewpoint: The road to addressing Long Covid.
vendredi, 30 juillet 2021 15:32 Écrit par Zouhair SouissiThe road to addressing Long Covid – Science (a few articles per month are free) Related: Review: Long covid—mechanisms, risk factors, and management. Commentary on Twitter On #LongCovid, @Dr2NisreenAlwan, a leading authority on this condition, has an exceptional perspective @ScienceMagazine today reviewing what we know, which is grossly insufficient, and what we need to […]
The post Viewpoint: The road to addressing Long Covid. appeared first on Links Medicus.
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
vendredi, 30 juillet 2021 15:32 Écrit par Zouhair SouissiCOVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence News release: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca […]
The post NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis. appeared first on Links Medicus.
Cohort study: Postdiagnosis smoking cessation linked to reduced risk for lung cancer progression and mortality.
jeudi, 29 juillet 2021 14:17 Écrit par Zouhair SouissiPostdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text) Commentary: Never too late: Cancer centers push patients to quit smoking – STAT Summary for Patients: Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and […]
The post Cohort study: Postdiagnosis smoking cessation linked to reduced risk for lung cancer progression and mortality. appeared first on Links Medicus.
What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination.
jeudi, 29 juillet 2021 14:16 Écrit par Zouhair SouissiWhat is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination – The Conversation
The post What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination. appeared first on Links Medicus.
Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show.
jeudi, 29 juillet 2021 14:16 Écrit par Zouhair SouissiEfficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show – STAT Original study (preprint): Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine – medRxiv Commentary on Twitter (thread – click for more) 6-month followup for major BNT-Pfizer vax trial. While still blinded, overall vaccine efficacy was: – […]
The post Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show. appeared first on Links Medicus.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
jeudi, 29 juillet 2021 14:16 Écrit par Zouhair SouissiIvermectin for preventing and treating COVID‐19 – Cochrane Library Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library Commentary: Ivermectin treatment in humans for COVID-19 – Liverpool School of Tropical Medicine Related: Why was a major study on ivermectin for covid-19 just retracted? RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19. Ivermectin […]
The post Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19. appeared first on Links Medicus.
PRINCIPLE RCT: Doxycycline does not improve outcomes in outpatients with suspected COVID-19 at high risk for adverse outcomes.
jeudi, 29 juillet 2021 14:16 Écrit par Zouhair SouissiDoxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet Respiratory Medicine Commentary: PRINCIPLE: a community-based COVID-19 platform trial – The Lancet Respiratory Medicine Commentary on Twitter NEW Research—In suspected #COVID19 in the community, doxycycline […]
The post PRINCIPLE RCT: Doxycycline does not improve outcomes in outpatients with suspected COVID-19 at high risk for adverse outcomes. appeared first on Links Medicus.
